Treatment Information

Back

Liver Cancer treatment details. Chemotherapy, Biologic therapy.

Queen Mary Hospital, Hong Kong, China.

Survival: monthsCountry:China
Toxiciy Grade:5City/State/Province:Hong Kong
Treatments:Chemotherapy, Biologic therapyHospital:Queen Mary Hospital
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
This study involved 27 patients with advanced hepatocellular carcinoma. The median age was 52 years and 92.6% were male.

Treatment:
Patients in this study were given a combination of a biologic therapy called PTK787/ZK222584, or PTK and the chemotherapy agent doxorubicin. PTK targets tyrosine kinase and VEGF receptor proteins in cancer cells, which leads to cell death. Another name for PTK is vatalanib.

Toxicities:
Two deaths due to hemorrhagic complications were reported in this study. Other reported toxicities included nausea, alopecia, and mucositis (inflammation of the stomach and mouth).

Results:
The median progression free survival was 5.4 months. Median overall survival was 7.3 months.

Support:
This study was partially supported by Novartis, makers of vatalanib.

Correspondence: Dr. Ronnie T. Poon; email: [email protected]



Back